Teal Health

Market position

Teal Health describes the Teal Wand as the first and most accurate FDA-authorized self-collection device for at-home cervical cancer screening in the U.S. market. Its authorization arrived as the USPSTF included self-collection in draft recommendations and as the industry shifted toward primary HPV testing; the company notes that 2026 screening guidance was updated to include at-home self-collection for primary HPV testing. Coverage of the company situates it within growing investor interest in women's health technology, an area that saw roughly $680 million invested across 30 deals in 2024 per Deloitte data.

The company differentiates on the combination of FDA authorization for at-home self-collection, clinical equivalence to clinician-collected samples (96% detection of cervical precancer; relative sensitivity of 1.00 for CIN2+ versus clinician collection), consumer-grade product and instruction design, and a bundled telehealth care pathway rather than a standalone test kit. In its clinical study, 94% of participants preferred the Teal Wand to in-clinic screening.

Technology

The Teal Wand is an ergonomic self-collection device, operating similarly to a tampon applicator with a large swab, designed to work across varying body weights, vaginal lengths and uterine orientations. Samples are analyzed using the same FDA-approved primary high-risk HPV test used in clinical settings. Supporting technology includes a telehealth platform with virtual visits, provider messaging, a secure results portal, and consumer-oriented printed and video instructions for use developed with illustrated, plain-language guidance.

Go-to-market

Direct-to-consumer online ordering through the company's website with virtual clinical visits, launched first in California in June 2025 and extended to additional states. The company pursued insurance coverage discussions with carriers to have the screening covered as preventive care, and has announced collaborations with academic health systems (UC Davis Health, WashU Medicine) to embed at-home screening in health system workflows. Marketing leans on peer-reviewed publication, clinician endorsements, and awards recognition.

People aged 25-65 with a cervix who are due for routine cervical cancer screening, with emphasis on those who are behind on screening due to access, scheduling or discomfort barriers, including first-time screeners, patients with past trauma or vaginismus, menopausal patients, and women in rural areas. The company also sells into health systems seeking to reach under-screened patients.

Geography

Headquartered in San Francisco, California, operating in the United States. The product launched in California in June 2025 with expansion across multiple states; the SELF-CERV trial spanned 16 sites nationwide.

History

The company developed the Teal Wand prototype starting roughly five years before 2025 and validated it through SELF-CERV, a nationwide clinical trial run across 16 academic and community sites with more than 600 participants. It received a $1.68 million Small Business Innovation Research grant from the National Cancer Institute and FDA Breakthrough Device designation, then closed an additional $10 million in seed funding in January 2025 while its FDA submission was under review, bringing total disclosed funding at that point to $23 million. The FDA granted marketing authorization in May 2025, and the company began rolling out the product in California in June 2025 before expanding across additional states. Clinical validation results were published in JAMA Network Open in May 2025. In 2026 the company announced work with health systems including UC Davis Health and WashU Medicine.

Risks & controversies

The business depends on regulatory authorization and on payer coverage decisions; the company notes it cannot currently serve Medicaid or Medi-Cal patients, even as cash-pay, and that insurance network coverage is still expanding. Operating a regulated device across multiple states introduces state-by-state commercialization and reimbursement complexity.